# Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine

> **NIH NIH U01** · BARUCH S. BLUMBERG INSTITUTE · 2024 · $349,569

## Abstract

Impact of pre-analytic procurement and processing variables on the detection of HCC DNA in urine
Hepatocellular carcinoma (HCC) is the world’s 2nd leading cause of cancer-related death and one of the
fastest-growing cancers in the US; 85% of patients die within 5 years, mainly due to late detection, limited
treatment options, and high recurrence. Currently, HCC recurrence and treatment responses are monitored
by serum AFP and serial imaging. Unfortunately, serum AFP can only be used for ~50% of HCC cases due
to low sensitivity. While MRI/CT imaging is the gold standard for diagnosis, it is expensive and less accessible.
It also has limited utility in the detection of small tumors (< 2 cm) and is challenging in the presence of
dysplastic nodules. Early detection of recurrent HCC is ineffective with the current available methods. Genetic
liquid biopsies have been routinely used in clinics for almost all cancer types as part of the National
Comprehensive Cancer Network (NCCN) guideline. However, its usage in HCC is limited even though its
promises have been well documented in the literature, mostly for blood and some for urine. Our hypothesis
is that by establishing an evidence-based biospecimen practice for urine collection, storage, and transrenal
DNA (trDNA) isolation, urine HCC DNA analysis with tailored sensitive assays can provide HCC genetics with
more frequent tumor surveillance and treatment response assessment compared to current standard of care
for prognosis. As a pioneer in developing urine cancer liquid biopsies, we have established the standard
operating procedure (SOP) for urine collection for the Early Detection Research Network colon cancer
validation study (protocol ID: 320) and other non-urinary tract cancers. We have identified pre-analytic
variables that influence urine HCC DNA assay performance in the process of developing an HCC urine DNA
test for HCC liquid biopsies. In this application, we propose to use a liver-specific trDNA marker, hepatitis B
virus (HBV) DNA, which is found in urine, from patients with chronic HBV infection to validate and mitigate
these pre-analytic variables. Aims 1 and 2, will identify, validate, and mitigate pre-analytic factors, associated
with urine collection, storage and processing for trDNA isolation, and characterize of the size of trDNA that
influences clinical assay results and reproducibility. As a result, an evidence-based urine biospecimen
practice can be established to help support urine HCC DNA assay development, validation for HCC genetic
liquid biopsy and assessment of treatment response. In Aim 3, we will then demonstrate the reproducibility
and clinical validation of the utility of urine HCC DNA in assessing responses to HCC treatment. Developing
a robust evidence-based urine biospecimen practice for sample collection, processing, and long-term storage
will lead to the validation of urine tests for assessing HCC treatment in clinical trials.

## Key facts

- **NIH application ID:** 10767786
- **Project number:** 5U01CA275648-02
- **Recipient organization:** BARUCH S. BLUMBERG INSTITUTE
- **Principal Investigator:** Ying-Hsiu Su
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $349,569
- **Award type:** 5
- **Project period:** 2023-02-01 → 2028-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10767786

## Citation

> US National Institutes of Health, RePORTER application 10767786, Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine (5U01CA275648-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10767786. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*